Emyria Ltd (AU:EMD) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Emyria Ltd achieved a milestone with over $1 million in clinical billings, marking a 36% revenue increase in mental health services compared to the previous year. The company is expanding its innovative mental health treatments, including the opening of a new Empax Centre and the authorization of Australia’s first female prescriber for MDMA-assisted therapy. Additionally, Emyria secured $2.3 million from investors and non-dilutive government funding to support the growth of services and the development of novel treatments for PTSD and Parkinson’s disease.
For further insights into AU:EMD stock, check out TipRanks’ Stock Analysis page.